Browsing Tag
CureVac N.V.
1 post
CureVac stock surges as BioNTech announces strategic mRNA-focused acquisition
BioNTech acquires CureVac in a $1.25B all-stock deal to expand its mRNA cancer pipeline. Includes stock insights, premium terms, and investor sentiment.